Sergei Syrbu

2.5k total citations
66 papers, 910 citations indexed

About

Sergei Syrbu is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Sergei Syrbu has authored 66 papers receiving a total of 910 indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Pathology and Forensic Medicine, 24 papers in Genetics and 21 papers in Oncology. Recurrent topics in Sergei Syrbu's work include Lymphoma Diagnosis and Treatment (41 papers), Chronic Lymphocytic Leukemia Research (22 papers) and Viral-associated cancers and disorders (12 papers). Sergei Syrbu is often cited by papers focused on Lymphoma Diagnosis and Treatment (41 papers), Chronic Lymphocytic Leukemia Research (22 papers) and Viral-associated cancers and disorders (12 papers). Sergei Syrbu collaborates with scholars based in United States, Italy and France. Sergei Syrbu's co-authors include Brian K. Link, Thomas M. Habermann, James R. Cerhan, Matthew J. Maurer, Stephen M. Ansell, Thomas E. Witzig, William R. Macon, Grzegorz S. Nowakowski, Carrie A. Thompson and Susan L. Slager and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Sergei Syrbu

59 papers receiving 904 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sergei Syrbu United States 16 544 399 259 173 149 66 910
Carsten Hirt Germany 18 774 1.4× 449 1.1× 433 1.7× 181 1.0× 162 1.1× 42 1.1k
Ciara L. Freeman United States 15 335 0.6× 451 1.1× 173 0.7× 279 1.6× 134 0.9× 87 934
Markus Kreuz Germany 19 601 1.1× 392 1.0× 210 0.8× 392 2.3× 180 1.2× 50 1.0k
Martha Glenn United States 15 334 0.6× 275 0.7× 250 1.0× 206 1.2× 138 0.9× 41 813
Markus Tiemann Germany 17 230 0.4× 407 1.0× 83 0.3× 177 1.0× 248 1.7× 73 959
Rosaria De Filippi Italy 19 453 0.8× 467 1.2× 293 1.1× 307 1.8× 386 2.6× 61 1.2k
C Lavignac France 8 504 0.9× 369 0.9× 249 1.0× 260 1.5× 134 0.9× 14 836
Hyun Jung Jun South Korea 18 314 0.6× 617 1.5× 133 0.5× 305 1.8× 124 0.8× 39 1.2k
Pilar Lardelli Spain 19 354 0.7× 643 1.6× 122 0.5× 298 1.7× 135 0.9× 71 1.5k
Cristiana Carniti Italy 21 245 0.5× 439 1.1× 169 0.7× 396 2.3× 314 2.1× 59 1.2k

Countries citing papers authored by Sergei Syrbu

Since Specialization
Citations

This map shows the geographic impact of Sergei Syrbu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sergei Syrbu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sergei Syrbu more than expected).

Fields of papers citing papers by Sergei Syrbu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sergei Syrbu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sergei Syrbu. The network helps show where Sergei Syrbu may publish in the future.

Co-authorship network of co-authors of Sergei Syrbu

This figure shows the co-authorship network connecting the top 25 collaborators of Sergei Syrbu. A scholar is included among the top collaborators of Sergei Syrbu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sergei Syrbu. Sergei Syrbu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tun, Aung M., Arushi Khurana, Raphael Mwangi, et al.. (2022). Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study. Blood Advances. 6(17). 5210–5221. 7 indexed citations
2.
Castellino, Alessia, Yucai Wang, Melissa C. Larson, et al.. (2021). Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes. Blood Advances. 6(4). 1350–1360. 13 indexed citations
3.
Wang, Yucai, Melissa C. Larson, Alessia Castellino, et al.. (2021). Event-Free Survival at 24 Months (EFS24) Becomes an Important Clinical Endpoint in Newly Diagnosed Mantle Cell Lymphoma in the New Era. Blood. 138(Supplement 1). 2429–2429. 2 indexed citations
4.
Casulo, Carla, Myla Strawderman, Raphaël Steiner, et al.. (2020). Describing Treatment of Primary Mediastinal Large B Cell Lymphoma Using Rigorously Defined Molecular Classification: A Retrospective Analysis. Blood. 136(Supplement 1). 35–36.
5.
Hoffman, Henry T., et al.. (2020). Mantle Cell Lymphoma Involving Major and Minor Salivary Glands With Parotid Sparing. JAMA Otolaryngology–Head & Neck Surgery. 146(3). 309–309. 2 indexed citations
6.
Tracy, Sean, Melissa C. Larson, Andrew L. Feldman, et al.. (2019). The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non‐follicular indolent B‐cell lymphomas. American Journal of Hematology. 94(6). 658–666. 13 indexed citations
7.
Mondello, Patrizia, Angelo Famà, Melissa C. Larson, et al.. (2019). Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma. Blood. 134(Supplement_1). 121–121. 5 indexed citations
8.
9.
Tracy, Sean, Thomas M. Habermann, Andrew L. Feldman, et al.. (2017). Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression. Haematologica. 103(2). 297–303. 16 indexed citations
10.
Syrbu, Sergei, et al.. (2016). Destructive soft tissue mass in the maxilla/maxillary sinus. Oral Surgery Oral Medicine Oral Pathology and Oral Radiology. 125(6). 510–515. 2 indexed citations
11.
Thodima, Venkata J., Marie‐Aline Charles, Asha Guttapalli, et al.. (2015). Cross-platform assessment of genomic imbalance confirms the clinical relevance of genomic complexity and reveals loci with potential pathogenic roles in diffuse large B-cell lymphoma. Leukemia & lymphoma. 57(4). 899–908. 5 indexed citations
12.
13.
Wondergem, Mariëlle J., Ken Herrmann, Sergei Syrbu, et al.. (2014). 18 F-fluorothymidine uptake in follicular lymphoma and error-prone DNA repair. EJNMMI Research. 4(1). 3–3. 2 indexed citations
14.
Syrbu, Sergei & Michael B. Cohen. (2011). An Enhanced Antigen-Retrieval Protocol for Immunohistochemical Staining of Formalin-Fixed, Paraffin-Embedded Tissues. Methods in molecular biology. 717. 101–110. 35 indexed citations
15.
Cerhan, James R., Thomas M. Habermann, Matthew J. Maurer, et al.. (2010). Genetic Polymorphisms In Genes Involved In R-CHOP Metabolism and Event-Free and Overall Survival In Diffuse Large B-Cell Lymphoma. Blood. 116(21). 996–996. 3 indexed citations
16.
Syrbu, Sergei, et al.. (2009). Epstein-Barr Virus Mimicking Lymphoma on FDG-PET/CT. Clinical Nuclear Medicine. 34(12). 891–893. 24 indexed citations
17.
Maurer, Matthew J., Thomas E. Witzig, William R. Macon, et al.. (2008). Diffuse Large B-Cell Lymphoma (DLBCL) Patients with Composite Histology Have Improved Early Outcome Compared to De Novo DLBCL When Treated with R-CHOP. Blood. 112(11). 2819–2819. 1 indexed citations
18.
Weiner, Ronald E., et al.. (2001). Early detection of oleic acid-induced lung injury in rats using (111)In-labeled anti-rat intercellular adhesion molecule-1.. PubMed. 42(7). 1109–15. 23 indexed citations
19.
Syrbu, Sergei, et al.. (1999). Phosphorylation of Cytosolic Phospholipase A2 and the Release of Arachidonic Acid in Human Neutrophils. The Journal of Immunology. 162(4). 2334–2340. 74 indexed citations
20.
Syrbu, Sergei, et al.. (1995). Increased Immunoreactive Rat Lung Icam-1 in Oleic Acid-Induced Lung Injury. Experimental Lung Research. 21(4). 599–616. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carsten Hirt Breakdown of academic impact, for papers by Ciara L. Freeman Breakdown of academic impact, for papers by Markus Kreuz Breakdown of academic impact, for papers by Martha Glenn Breakdown of academic impact, for papers by Markus Tiemann Breakdown of academic impact, for papers by Rosaria De Filippi Breakdown of academic impact, for papers by C Lavignac Breakdown of academic impact, for papers by Hyun Jung Jun Breakdown of academic impact, for papers by Pilar Lardelli Breakdown of academic impact, for papers by Cristiana Carniti
Rankless by CCL
2026